Taking people in FranceNo phase
Measures CALR gene levels in patients with blood cell disorders over time
Checks CALR gene levels in adults with CALR-mutated myeloproliferative disease to track progression.
Key facts
- Who runs it
- University Hospital, Angers
- Where
- Angers, Bordeaux, Brest, Cholet, Le Mans, Morlaix, Paris, Poitiers, Quimper, and Tours, FranceSee the 10 sites
- Trial code
- Registry title
- Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
- Status
- Recruiting
- People taking part
- 260 people, planned
- Started
- 28 Oct 2021
- Expected to end
- 28 Apr 2030
- Type of study
- Interventional
- Treatments tested
- CALR allele burden quantification
- Record updated
- 6 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a myeloproliferative neoplasm that has a CALR gene change, diagnosed between 2006 and 2020, with a stored sample from diagnosis or before treatment.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Myeloproliferative neoplasm with a CALR mutation, diagnosed between 2006 and 2020
- Earlier treatment
- At least one sample must be available from the time of diagnosis or from before treatment to reduce blood cell counts (cytoreductive treatment).
- Biomarker or test result
- CALR mutation
Main reasons for not taking part
- Another active blood disease or cancer at the time of diagnosis
- A person under a legal protection scheme
- A person who cannot give consent
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- adults (age ≥18 years),
- affiliated to the national social security system,
- with CALR mutated myeloproliferative neoplasm diagnosed between 2006 - 2020,
- for which at least one sample is available at the time of diagnosis or before cytoreductive treatment,
- who signed the consent to participate in the study,
- included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM)
Who cannot take part
- patient with another active hematological disease or cancer at the time of diagnosis,
- person subject to legal protection scheme or incapable of giving consent
Where in France
- CHU AngersAngers, FranceContact: Laurane COTTIN, DrTaking people
- CHU BordeauxBordeaux, FranceContact: Olivier MANSIER, DOCTORTaking people
- Chu BrestBrest, FranceContact: ERIC LIPPERT, PROFESSORTaking people
- CH CholetCholet, FranceContact: CHARLES BESCOND, DOCTORTaking people
- CH Le MansLe Mans, FranceContact: KAMEL LARIBI, DOCTORTaking people
- CH MorlaixMorlaix, FranceContact: CHRISTOPHE NICOL, DOCTORTaking people
- AP-HP Henri MondorParis, FranceContact: Lydia ROY, DOCTORTaking people
- CHU PoitiersPoitiers, FranceContact: Jose Miguel TORREGROSA-DIAZ, DOCTORTaking people
- CH QuimperQuimper, FranceContact: Lenaig LE CLECH, DOCTORTaking people
- CHU ToursTours, FranceContact: Olivier HERAULT, PROFESSORTaking people
About the trial
What the trial wants to find out
Prospective study to evaluate the relevance of CALR allele burden monitoring as a molecular marker of disease progression.
The group in the trial
- CALRSUIVI cohortTreatment being tested
Treatment: CALR allele burden quantification
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
- Plain-language title
- Measures CALR gene levels in patients with blood cell disorders over timeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 March 2026